Abstract
The autosomal dominant disease tuberous sclerosis (TSC) is caused by mutations in either TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16p13.3, encoding tuberin. TSC is characterized by hamartomas that occur in many organs of affected patients and these have been considered to likely result from defects in proliferation control. Although the true biochemical functions of the two TSC proteins have not been clarified, a series of independent investigations demonstrated that modulated hamartin or tuberin expression cause deregulation of proliferation/cell cycle in human, rodent and Drosophila cells. In support of tuberin acting as a tumor suppressor, ectopic overexpression of TSC2 has been shown to decrease proliferation rates of mammalian cells. Furthermore, overexpression of TSC2 has been demonstrated to trigger upregulation of the cyclin-dependent kinase inhibitor p27. We report that three different naturally occurring and TSC causing mutations within the TSC2 gene elliminate neither the anti-proliferative capacity of tuberin nor tuberin's effects on p27 expression. For the first time these data provide strong evidence that deregulation of proliferation and/or upregulation of p27 are not likely to be the primary/only mechanisms of hamartoma development in TSC. These results demand reassessment of previous hypotheses of the pathogenesis of TSC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aicher LD, Campbell JS, Yeung RS . 2001 J. Biol. Chem. in press
Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Bessho M, Jensen RA, Liu ET . 1999 Proc. Natl. Acad. Sci. USA 96: 11866–11871
Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJJ, Sampson JR, Wienecke R, DeClue JE . 2000 Oncogene 19: 6306–6316
Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ . 2000 Hum. Genet. 107: 97–114
Gomez MR, Sampson JR, Whittemore VH . 1999 Tuberous Sclerosis Complex, 3rd edn Oxford University Press, New York, NY
Hengstschläger M, Braun K, Soucek T, Miloloza A, Hengstschläger-Ottnad E . 1999 Mutat. Res. 436: 1–9
Henry KW, Yuan X, Koszewski NJ, Onda DJ, Kwiatkowski DJ, Noonan DJ . 1998 J. Biol. Chem. 273: 20535–20539
Ito N, Rubin GM . 1999 Cell 96: 529–539
Jin F, Wienecke R, Xiao G-H, Maize JC, DeClue JE, Yeung RS . 1996 Proc. Natl. Acad. Sci. USA 93: 9154–9159
Kalejta RF, Shenk T, Beavis AJ . 1997 Cytometry 29: 286–291
Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O . 1995 Nature Genet. 9: 70–74
Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A . 2000 Nature Cell Biol. 2: 281–287
Maheshwar MM, Cheadle JP, Jones AC, Myring J, Fryer AE, Harris PC, Sampson JR . 1997 Hum. Mol. Genet. 6: 1991–1996
Miloloza A, Rosner M, Nellist M, Halley D, Bernaschek G, Hengstschläger M . 2000 Hum. Mol. Genet. 9: 1721–1727
Nellist M, Van Slegtenhorst MA, Goedbloed M, Ouweland AMW. van den, Halley DJ, Sluijs P. van der . 1999 J. Biol. Chem. 275: 35647–35652
Ohtsubo M, Roberts JM . 1993 Science 259: 1908–1912
Orimoto K, Tsuchiya H, Kobayashi T, Matsuda T, Hino O . 1996 Biochem. Biophys. Res. Com. 219: 70–75
Pajak L, Jin F, Xiao GH, Soonpaa MH, Field LJ, Yeung RS . 1997 Am. J. Physiol. 273: 1619–1627
Pasumarthi KBS, Nakajima H, Nakaji HO, Jing S, Field LJ . 2000 Circ. Res. 86: 1069–1077
Plank TL, Yeung RS, Henske EP . 1998 Cancer Res. 58: 4766–4770
Sambrook J, Fritsch EF, Maniatis T . 1989 Molecular cloning-a laboratory manual Cold Spring Harbor Laboratory Press, USA
Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschläger M . 1997 J. Biol. Chem. 272: 29301–29308
Soucek T, Hölzl G, Bernaschek G, Hengstschläger M . 1998a Oncogene 16: 2197–2204
Soucek T, Yeung RS, Hengstschläger M . 1998b Proc. Natl. Acad. Sci. USA 95: 15653–15658
The European Chromosome 16 Tuberous Sclerosis Consortium . 1993 Cell 75: 1305–1315
The TSC1 Consortium . 1997 Science 277: 805–808
Tsuchiya H, Orimoto K, Kobayashi T, Hino O . 1996 Cancer Res. 56: 429–433
Van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, Ouweland A, van den, Reuser A, Sampson J, Halley D, Sluijs P. van der . 1998 Hum. Mol. Genet. 7: 1053–1057
Wienecke R, König A, DeClue JE . 1995 J. Biol. Chem. 270: 16409–16414
Xiao G-H, Shoarinejad F, Jin F, Golemis EA, Yeung RS . 1997 J. Biol. Chem. 272: 6097–6100
Yeung RS, Xiao G-H, Jin F, Lee W-C, Testa JR, Knudson AG . 1994 Proc. Natl. Acad. Sci. USA 91: 11413–11416
Young J, Povey S . 1998 Mol. Med. Today, July 313–319
Acknowledgements
The authors wish to thank AJ Beavis, J DeClue, M Eilers and R Yeung for the generous gift of cell lines and reagents, N Maderner for help with statistics, E Hengstschläger-Ottnad for helpful discussion and M Schreiber for critically reading the manuscript. Work in M Hengstschläger's laboratory is funded by the Austrian Federal Ministry of Science and Transport (GZ 70.037/2-Pr/4/98). M Kubista is supported by the Austrian Ludwig Boltzmann Institute for Clinical and Experimental Oncology. JR Sampson and JP Cheadle are supported by the Tuberous Sclerosis Alliance and the Tuberous Sclerosis Association.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soucek, T., Rosner, M., Miloloza, A. et al. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression. Oncogene 20, 4904–4909 (2001). https://doi.org/10.1038/sj.onc.1204627
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204627